

Juan Marcos González

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4974380/publications.pdf>

Version: 2024-02-01

66
papers

1,583
citations

567281

15
h-index

315739

38
g-index

67
all docs

67
docs citations

67
times ranked

2236
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | What is a Good Death? A Choice Experiment on Care Indicators for Patients at End of Life. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 457-467. | 1.2 | 10 |
| 2 | Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008797. | 3.9 | 7 |
| 3 | Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 827305. | 4.8 | 3 |
| 4 | Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report. <i>Value in Health</i> , 2022, 25, 685-694. | 0.3 | 23 |
| 5 | Surgical treatment for recurrent shoulder instability: factors influencing surgeon decision making. <i>Journal of Shoulder and Elbow Surgery</i> , 2021, 30, e85-e102. | 2.6 | 14 |
| 6 | Parental preferences for vesicoureteral reflux treatment: Profile case best-worst scaling. <i>Journal of Pediatric Urology</i> , 2021, 17, 86.e1-86.e9. | 1.1 | 0 |
| 7 | Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. <i>JCO Oncology Practice</i> , 2021, 17, e1639-e1648. | 2.9 | 4 |
| 8 | The Impact of the Risk Functional Form Assumptions on Maximum Acceptable Risk Measures. <i>Patient</i> , 2021, 14, 827-836. | 2.7 | 6 |
| 9 | Incomplete information and irrelevant attributes in stated preference values for health interventions. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2637-2648. | 1.7 | 2 |
| 10 | The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. <i>Gynecologic Oncology</i> , 2021, 162, 440-446. | 1.4 | 2 |
| 11 | Who Would Pay Higher Taxes for Better Mental Health? Results of a Large-Sample National Choice Experiment. <i>Milbank Quarterly</i> , 2021, 99, 771-793. | 4.4 | 5 |
| 12 | Stratified psoriasis treatment plans: why is patient preference information needed?. <i>British Journal of Dermatology</i> , 2021, 185, 882-883. | 1.5 | 0 |
| 13 | Heterogeneity in Parent Preferences for Peanut Desensitization Therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3459-3465. | 3.8 | 1 |
| 14 | Quantifying Value of Hope. <i>Value in Health</i> , 2021, 24, 1511-1519. | 0.3 | 13 |
| 15 | <p>Why Do People Living with HIV Adhere to Antiretroviral Therapy and Not Comorbid Cardiovascular Disease Medications? A Qualitative Inquiry</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 985-994. | 1.8 | 4 |
| 16 | Patient Preferences for Surgical Treatment of Knee Osteoarthritis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 2022-2031. | 3.0 | 10 |
| 17 | Do Patient Preferences Align With Value Frameworks? A Discrete-Choice Experiment of Patients With Breast Cancer. <i>MDM Policy and Practice</i> , 2020, 5, 238146832092801. | 0.9 | 3 |
| 18 | Patient Preferences Around Extent of Surgery in Low-Risk Thyroid Cancer: A Discrete Choice Experiment. <i>Thyroid</i> , 2020, 30, 1044-1052. | 4.5 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. <i>Gynecologic Oncology</i> , 2020, 156, 561-567. | 1.4 | 21 |
| 20 | A Guide to Measuring and Interpreting Attribute Importance. <i>Patient</i> , 2019, 12, 287-295. | 2.7 | 62 |
| 21 | Parental Preferences for Vesicoureteral Reflux Treatment: A Crowd-sourced, Best-worst Scaling Study. <i>Urology</i> , 2019, 128, 71-77. | 1.0 | 4 |
| 22 | Patients'™ Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008051. | 3.9 | 14 |
| 23 | Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). <i>Contemporary Clinical Trials</i> , 2019, 76, 120-131. | 1.8 | 12 |
| 24 | Trading Health Risks for Glory: A Reformulation of the Goldman Dilemma. <i>Sports Medicine</i> , 2018, 48, 1963-1969. | 6.5 | 7 |
| 25 | Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis. <i>Patient</i> , 2018, 11, 285-300. | 2.7 | 15 |
| 26 | Symposium Title: Preference Evidence for Regulatory Decisions. <i>Patient</i> , 2018, 11, 467-473. | 2.7 | 7 |
| 27 | Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment. <i>Pharmacoeconomics</i> , 2018, 36, 973-986. | 3.3 | 15 |
| 28 | Patient Preferences for Health States Following Alternative Management Options for Ductal Carcinoma in Situ. <i>Value in Health</i> , 2018, 21, S11-S12. | 0.3 | 0 |
| 29 | Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment. <i>British Journal of Dermatology</i> , 2017, 176, 777-785. | 1.5 | 26 |
| 30 | Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. <i>Value in Health</i> , 2017, 20, 32-39. | 0.3 | 19 |
| 31 | Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. <i>Cancer Management and Research</i> , 2017, Volume 9, 149-158. | 1.9 | 15 |
| 32 | Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors. <i>Patient</i> , 2016, 9, 323-333. | 2.7 | 11 |
| 33 | Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. <i>Value in Health</i> , 2016, 19, 300-315. | 0.3 | 782 |
| 34 | What are people willing to pay for whole-genome sequencing information, and who decides what they receive?. <i>Genetics in Medicine</i> , 2016, 18, 1295-1302. | 2.4 | 21 |
| 35 | Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons'™ Referrals. <i>Annals of Surgical Oncology</i> , 2016, 23, 3510-3517. | 1.5 | 6 |
| 36 | Estimating conditional certainty equivalents using choice-experiment data. <i>Journal of Choice Modelling</i> , 2015, 15, 14-25. | 2.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | What are people willing to pay for whole genome sequencing information?. Value in Health, 2015, 18, A285-A286. | 0.3 | 0 |
| 38 | Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments. Journal of Thyroid Research, 2015, 2015, 1-8. | 1.3 | 14 |
| 39 | Physicians'™ Preferences for Bone Metastases Drug Therapy in the United States. Value in Health, 2015, 18, 78-83. | 0.3 | 22 |
| 40 | Incorporating patient-preference evidence into regulatory decision making. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 2984-2993. | 2.4 | 182 |
| 41 | Patients'™ And Physicians'™ Time Trade-Off Preferences For Adverse Outcomes Associated With Metastatic Colorectal Cancer Treatments. Value in Health, 2015, 18, A9. | 0.3 | 0 |
| 42 | Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with Anticoagulants in Atrial Fibrillation™evidence from the United States and Japan. Value in Health Regional Issues, 2015, 6, 65-72. | 1.2 | 18 |
| 43 | Patients' and physicians' risk-benefit trade-off preferences for metastatic colorectal cancer treatments.. Journal of Clinical Oncology, 2015, 33, 3591-3591. | 1.6 | 6 |
| 44 | Patient preferences for treatments to delay bone metastases. Prostate, 2014, 74, 1488-1497. | 2.3 | 20 |
| 45 | Physicians'™ Preferences for Bone Metastases Treatments in Canada. Value in Health, 2014, 17, A93. | 0.3 | 0 |
| 46 | Preferences for treatment to delay bone metastases (BM) in patients with castration-resistant prostate cancer (CRPC) at high risk of developing BM.. Journal of Clinical Oncology, 2014, 32, 117-117. | 1.6 | 0 |
| 47 | Stated time-allocation, adherence, and health-outcome tradeoff preferences in cystic fibrosis households. Value in Health, 2013, 16, A26. | 0.3 | 0 |
| 48 | Patient And Physician Preferences In The United States For Benefits And Risks Of Anticoagulant Use In Atrial Fibrillation ™ Results From A Conjoint-Analysis Study. Value in Health, 2013, 16, A11. | 0.3 | 2 |
| 49 | Patients at the Center of Regulatory Decisions: Using Stated-Preference Data to Help Regulators Answer Difficult Questions. Value in Health, 2013, 16, A387. | 0.3 | 1 |
| 50 | Psoriasis Patients'™ Tolerance for Therapeutic Risks in Return for Symptom Improvement in the United Kingdom. Value in Health, 2013, 16, A508. | 0.3 | 0 |
| 51 | Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Preference and Adherence, 2013, 7, 937. | 1.8 | 42 |
| 52 | PMS46 Patient Trade-Offs Between Frequency and Duration of Biologic Treatments for Rheumatoid Arthritis. Value in Health, 2012, 15, A42. | 0.3 | 0 |
| 53 | PND36 Structured Benefit-Risk Assessment of Triptan Treatments Using Patient-Preference Data. Value in Health, 2012, 15, A147. | 0.3 | 1 |
| 54 | PDB58 How Much Do Patients with Type 2 Diabetes Value Improvements in Dosing Convenience? Results from a Conjoint Study. Value in Health, 2011, 14, A482. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | PSY38 Estimating Healthy-Time Equivalents for Migraine Treatment Outcomes from Conjoint Analysis Measures of Patient Preferences. Value in Health, 2011, 14, A417. | 0.3 | 0 |
| 56 | Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Preference and Adherence, 2011, 5, 307. | 1.8 | 15 |
| 57 | Effects of interactions between solids and surfactants on the tribological properties of water-based drilling fluids. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2011, 391, 216-223. | 4.7 | 35 |
| 58 | The value to patients of reducing lesion severity in plaque psoriasis. Journal of Dermatological Treatment, 2011, 22, 266-275. | 2.2 | 27 |
| 59 | PSY48 THE VALUE TO PATIENTS OF TREATING PLAQUE PSORIASIS. Value in Health, 2010, 13, A214-A215. | 0.3 | 0 |
| 60 | PMC29 PATIENT PREFERENCE WEIGHTS FOR BENEFIT-RISK ANALYSIS: A STATIN CASE STUDY. Value in Health, 2010, 13, A19. | 0.3 | 1 |
| 61 | BL2 PATIENT PREFERENCES FOR BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS: A DISCRETE CHOICE EXPERIMENT. Value in Health, 2010, 13, A243. | 0.3 | 0 |
| 62 | PMS50 PATIENTS' STATED HEALTH-OUTCOME PREFERENCES FOR CONFOUNDED PATIENT-REPORTED OUTCOME DOMAINS FOR OSTEOARTHRITIS. Value in Health, 2010, 13, A312. | 0.3 | 0 |
| 63 | PMS52 PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH THE USE OF NSAIDS: EVIDENCE FROM PATIENTS DIAGNOSED WITH OSTEOARTHRITIS (OA) IN UK. Value in Health, 2010, 13, A312. | 0.3 | 0 |
| 64 | PMS68 PHYSICIANS' STATED PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH NSAID USE IN PATIENTS WITH OSTEOARTHRITIS IN UNITED KINGDOM. Value in Health, 2010, 13, A316. | 0.3 | 0 |
| 65 | UT3 HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE ROTAVIRUS INFECTIONS. Value in Health, 2009, 12, A224. | 0.3 | 0 |
| 66 | A Joint Estimation Method to Combine Dichotomous Choice CVM Models with Count Data TCM Models Corrected for Truncation and Endogenous Stratification. Journal of Agricultural & Applied Economics, 2008, 40, 681-695. | 1.4 | 16 |